Why rare genetic diseases are a logical focus for RNA therapies

Liam Drew

Nature, 2019, vol. 574, issue 7778, S16-S18

Abstract: When two pharmaceutical companies turned their attention to a rare condition, they came up with different strategies for targeting RNA. Now, RNA therapies for other hereditary conditions are within the sights of the industry.

Keywords: Therapeutics; Drug discovery (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-019-03075-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:574:y:2019:i:7778:d:10.1038_d41586-019-03075-5

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-019-03075-5

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().